OCGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 17, 2021 in the Class Action Filed on Behalf of Ocugen, Inc. Limited Shareholders
New York, New York--(Newsfile Corp. - June 23, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) alleging that the Company violated federal securities laws.
Class Period: February 2, 2021 and June 10, 2021
Lead Plaintiff Deadline: August 17, 2021
No obligation or cost to you.
Learn more about your recoverable losses in OCGN:
Ocugen, Inc. NEWS - OCGN NEWS
CLASS ACTION CASE DETAILS: The filed complaint alleges that Ocugen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Ocugen you have until August 17, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you purchased Ocugen securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/88442